Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5858-5866

  Sambol, Elliot B ^a   Ambrosini, Grazia ^a   Geha, Rula C ^a   Kennealey, Peter T ^a   DeCarolis, Penelope ^a   O'Connor, Rachael ^a   Wu, Yuhsin V ^a   Motwani, Monica ^a   Chen, Jin Hong ^a   Schwartz, Gary K ^a   Singer, Samuel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL; IMATINIB; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN MCL 1; RNA POLYMERASE; SMALL INTERFERING RNA; STEM CELL FACTOR; TRANSCRIPTION ELONGATION FACTOR; TYROSINE; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION TERMINATION; TUMOR CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; FLAVONOIDS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PHOSPHORYLATION; PIPERAZINES; PIPERIDINES; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RNA POLYMERASE II; TRANSCRIPTION, GENETIC;

EID: 33745259006     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2933     Document Type: Article

References (47)

1. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999;31:1037-51.
2. Tian Q, Frierson HF, Jr., Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154:1643-7.
3. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44.
4. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370-6.
5. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor. Cancer Res 2000;60:6757-62.
6. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
7. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
8. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
9. Buchdunger E, Cioffi CL, Law N, et al. Abl proteinryrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
10. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-8.
11. Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004;23:3999-4006.
12. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
13. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.
14. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
15. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004;10:4270-5s.
16. De Azevedo WF, Jr., Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A 1996;93:2735-40.
17. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004;104:509-18.
18. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003;63:230-5.
19. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276:31793-9.
20. Lu X, Burgan WE, Cerra MA, et al. Transcriptional signature of flavopiridol-induced tumor cell death. Mol Cancer Ther 2004;3:861-72.
21. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001;38:139-70.
22. Huang R, Lin Y, Wang CC, et al. Connexin 43 suppresses human glioblastoma cell growth by down-regulation of monocyte chemotactic protein 1, as discovered using protein array technology. Cancer Res 2002;62:2806-12.
23. Yamamoto K, Tojo A, Aoki N, Shibuya M. Characterization of the promoter region of the human c-kit protooncogene. Jpn J Cancer Res 1993;84:1136-44.
24. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. α1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003;9:625-32.
25. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92:3804-16.
26. Rudek MA, Bauer KS, Jr., Lush RM III, et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003;37:1369-74.
27. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96:393-7.
28. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidenlified ligand. EMBO J 1987;6:3341-31.
29. Thommes K, Lennartsson J, Carlberg M. Ronnstrand L. Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. Biochem J 1999;341:211-6.
30. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279:31655-63.
31. Kapur H, Chandra S, Cooper R. McCarthy J, Williams DA. Role of p38 and HRK MAP kinase in proliferation of erythroid progenitors in response to stimulation by soluble and membrane isoforms of stem cell factor. Blood 2002;100:1287-93.
32. Casteran N, De Sepulveda P, Beslu N. et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 2003;22:4710-22.
33. Ogawa K, Takeda Y, Tashima M, et al. High expression of c-kit in K562YO cells due to the prolonged half-life of its mRNA: the effects of modification with serine/threonine kinase signals. Blood 1995;85:1496-503.
34. Sims RJ III, Belotserkovskaya R. Reinberg D. Elongation by RNA polymerase II: the short and long of it. Genes Dev 2004;18:2437-68.
35. Marshall NF, Peng J, Xie Z., Price DII. Control of RNA polymerase II elongation potential by a novel carboxylterminal domain kinase. J Biol Chem 1996;271:27176-83.
36. Takada V. Aggarwal BB. Flavopiridol inhibits NF-κB activation induced by various carcinogens and inflammatory agents through inhibition of IκBα kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenasc-2, and matrix metalloprotease-9. J Biol Chem 2004;279:4750-9.
37. Nabta R. Trent S, Yang C, Schmidt KV. Epidermal growth factor receptor expression is a candidate target of the Synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Res 2003;63:3626-31.
38. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. NF-[K]B binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001;8:327-37.
39. Lis JT, Mason P. Pong J. Price DII, Werner J. P-TEFb kinase recruitment and function at heat shock loci. Genes Dev 2000;14:792-803.
40. Beppu K, Jaboine J. Merchant MS, Mackall CL, Thiele CJ. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004;96:46-55.
41. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol.com 2001;2:Research0041. Epub 2001 Sept 13.
42. Maki RG, Fletcher JA. Heinrich MC, et al. Results from a continuation trial of SU11248 in patients with imatinib (IM)-resistant gastrointestinal strornal tumors (GIST) [abstract #9011]. Proc Am Soc Clin Oncol 2005;23:818S.
43. Growney JD. Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib are sensitive to the lyrosine kinase inhibitor PKC412. Blood 2005;106:721-4.
44. Tatton L, Morley GM. Chopra R, Khwaja A. The Sre-selective kinase inhibitor PP1 also inhibits Kit and Her-Abl tyrosine kinases. J Biol Chem 2003;278:4847-53.
45. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-4.
46. Shah MA, Kortmansky J, Motwani M. et al. A phase J clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005;11:3836-45.
47. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805, Clin Cancer Res 2005;11:4176-81.